Role of the gut microbiota in MASLD-associated hepatocellular carcinoma: mechanistic insights and therapeutic targets
Year: 2026
Type: article
Abstract: Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly replacing viral hepatitis as a leading cause of hepatocellular carcinoma (HCC) worldwide. MASLD-related HCC (MASLD-HCC) displays a distinctive and complex biological phenotype, particularly in terms of its immune microenvironment and response to immunotherapy, however, the related underlying mechanisms remain insufficiently investigated. Recent studies have suggested a crucial role of the gut microbiota in regulating hepatic inflammatory and immune responses during the malignant transformation from MASLD to HCC, known as the gut-liver axis. In this review, the dynamic alterations in the gut microbiome during MASLD-HCC initiation and development are summarized. The relevant mechanisms, including the gut–liver axis, hepatic immune reprogramming and microbial metabolite-induced signalling pathways, are discussed in this review. Moreover, several potential microbiota-targeted strategies for preventing or treating MASLD-HCC, including dietary intervention, probiotics, antibiotics, fecal microbiota transplantation, natural products and plant-derived bioactive compounds, are evaluated. Finally, challenges and future directions for basic and translational research in this field are discussed. Taken together, these findings suggest that the gut microbiota is a novel diagnostic biomarker and therapeutic target for MASLD-HCC management.
Source: Frontiers in Immunology
Authors: Jiayu Chang(Investigation, Methodology, Project administration, Visualization, Writing – original draft), Jianing Zhu(Investigation, Methodology, Project administration, Visualization, Writing – original draft), Gaoyu Chen(Investigation, Methodology, Project administration, Visualization, Writing – original draft), Xin Chen(Data curation, Formal analysis, Visualization, Writing – original draft), Junfeng Yin(Data curation, Formal analysis, Resources, Writing – original draft), Mingyang Tao(Data curation, Formal analysis, Visualization, Writing – original draft), Yajuan Chu, Ying Wang(Data curation, Formal analysis, Funding acquisition, Supervision, Visualization, Writing – original draft), Yefei Zhu(Conceptualization, Funding acquisition, Resources, Supervision, Writing – review & editing), Yufang Chen, Xuebing Yan(Conceptualization, Funding acquisition, Resources, Supervision, Writing – review & editing)
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: gut microbiota, non-alcoholic fatty liver disease, hepatocellular carcinoma, gut-liver axis, hepatic immune microenvironment, microbial metabolites, immunotherapy response, dietary intervention, probiotics, antibiotics, fecal microbiota transplantation, phytochemicals, diagnostic biomarkers, therapeutic target
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234549980
